2-chloro-3-methoxyisonicotinonitrile | 1256811-48-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-chloro-3-methoxyisonicotinonitrile
• 英文别名: 2-Chloro-3-methoxyisonicotinonitrile；2-chloro-3-methoxypyridine-4-carbonitrile
• CAS: 1256811-48-9
• 化学式: C₇H₅ClN₂O
• 分子量: 168.583
• InChiKey: OZDJGMVPNGNEIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-3-methoxyisonicotinonitrile 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 potassium tert-butylate 、 sodium hydride 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  [EN] NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND
  [FR] COMPOSÉ DE PYRIDINE HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  [ZH] 一类含氮杂环吡啶类化合物

  摘要：

  一种含氮杂环类蛋白抑制剂化合物，其立体异构体，互变异构体或药学上可接受的盐，还提供了含氮杂环类化合物的制备及其用途，使用该类化合物制备的药物治疗疾病用途广泛，其中所述疾病包括多类型自身免疫性疾病，如多发性硬化，类风湿性关节炎，炎性肠病，红斑狼疮，神经性皮炎，皮炎，牛皮癣，牛皮癣性关节炎，克罗恩病，干燥综合征和硬皮病等。

  公开号：

  WO2022233286A1
• 作为产物：
  描述：

  2-氯-3-甲氧基吡啶 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 生成 2-chloro-3-methoxyisonicotinonitrile
  参考文献：
  名称：

  [EN] NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND
  [FR] COMPOSÉ DE PYRIDINE HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  [ZH] 一类含氮杂环吡啶类化合物

  摘要：

  一种含氮杂环类蛋白抑制剂化合物，其立体异构体，互变异构体或药学上可接受的盐，还提供了含氮杂环类化合物的制备及其用途，使用该类化合物制备的药物治疗疾病用途广泛，其中所述疾病包括多类型自身免疫性疾病，如多发性硬化，类风湿性关节炎，炎性肠病，红斑狼疮，神经性皮炎，皮炎，牛皮癣，牛皮癣性关节炎，克罗恩病，干燥综合征和硬皮病等。

  公开号：

  WO2022233286A1

文献信息

• [EN] PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016095204A1

  公开（公告）日：2016-06-23

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂吡咯烷化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• [EN] 2-PYRIDYLAMINO-4-NITRILE-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE 2-PYRIDYLAMINO-4-NITRILE-PIPÉRIDINYL, ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014085208A1

  公开（公告）日：2014-06-05

  The present invention is directed to 2-pyridylamino-4-nitrile-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridylamino-4-nitrile-piperidinyl compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶基氨基-4-硝基-哌啶基化合物，其是促进睡眠激素受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶基氨基-4-硝基-哌啶基化合物治疗或预防涉及促进睡眠激素受体的神经和精神疾病和疾病的用途。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗涉及促进睡眠激素受体的疾病中的用途。
• 2-PYRIDYLAMINO-4-NITRILE-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20150322039A1

  公开（公告）日：2015-11-12

  The present invention is directed to 2-pyridylamino-4-nitrile-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridylamino-4-nitrile-piperidinyl compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶基氨基-4-硝基哌啶基化合物，它们是促进睡眠的荷尔蒙受体拮抗剂。本发明还涉及上述2-吡啶基氨基-4-硝基哌啶基化合物在治疗或预防涉及荷尔蒙受体的神经系统和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗涉及荷尔蒙受体的疾病中的用途。
• Pyrrolidine orexin receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10150751B2

  公开（公告）日：2018-12-11

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及作为奥曲肽受体拮抗剂的吡咯烷化合物。本发明还涉及本文所述化合物在潜在治疗或预防涉及奥曲肽受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及奥曲肽受体的此类疾病中的用途。
• Substituted pyridines as TYK2 inhibitors
  申请人：FronThera U.S. Pharmaceuticals LLC

  公开号：US11053219B2

  公开（公告）日：2021-07-06

  Described herein are pyridine compounds of Formula (XIII) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation

  本文所述的式 (XIII) 吡啶化合物可用于治疗 TYK2 介导的疾病。在某些实施方案中，TYK2-介导的紊乱是自身免疫性紊乱、炎症性紊乱、增殖性紊乱、内分泌紊乱、神经紊乱或与移植相关的紊乱。